Introduction
Rheumatoid arthritis (RA) is a chronic autoimmune disease, typically characterized by symmetrical polyarthritis, joint destruction and an impaired quality of life (1) . The pathogenesis of RA remains to be elucidated. Numerous factors and inflammatory cells, including monocytes, B cells, T cells, endothelial cells and fibroblasts operate in unison to initiate a chronic inflammatory process (2) (3) (4) (5) . Increasing evidence has been obtained regarding the pivotal role of B cells involved in the immune dysregulation in RA, which is supported by the clinical improvements in the patients with RA receiving B-cell depleting therapies such as rituximab, an anti-CD20 antibody (6) (7) (8) (9) . However, the absence or loss of B cells was shown to exacerbate disease symptoms in experimental autoimmune encephalomyelitis, collagen-induced arthritis (CIA) and colitis, suggesting that B cells, or specific B-cell sub-sets, are also able to negatively regulate immune responses (10) (11) (12) (13) .
Suppressor B-cells were initially observed in 1974 for their suppressive effects on delayed hypersensitivity (14) . Further interest in suppressor B-cells was generated by studies demonstrating a profound inhibitory function in the inflammatory context, in vitro and in adoptive transfer experiments (15) (16) (17) (18) (19) (20) . Cumulative evidence suggested that a certain B-cell sub-set predominantly exerted regulatory functions through the production of the regulatory cytokine interleukin (IL)-10; this B-cell sub-set was therefore named as B10 cells (16) . Additional types of IL-10-producing or regulatory B10 cells also exist, including transforming growth factor-β producing B-cells (12, 17, 21, 22) . Dissimilar to the CD1d hi CD5 + CD19
hi sub-set in the spleen, which was labeled as B10 cells in mice, the identification of B10 cells using membrane markers has, thus far, not been successful in humans (23 (24) (25) (26) (27) . Contradictory to the findings in the animal models, the negative regulatory function of B10 cells was impaired in the patients with thrombocytopenia and systemic lupus erythematosus (SLE) (26, 28) . In the CIA model, B10 cells demonstrated their novel and effective suppressive effects as well as their potential therapeutic value in the in vivo treatment of severe RA, with resistance to current therapies (12) . However, the frequency of B10 cells in the patients with RA and the demonstration of their similar inhibitory effects to those found in animal models require further study.
In the present study, the frequency of B10 cells in the peripheral blood (PB) and their correlation with clinical characteristics, laboratory characteristics and inflammatory cytokines in a total of 97 patients with RA with different disease activity and status were investigated. In addition, the frequency of B10 cells in the paired synovial fluid (SF) from 13 patients was evaluated. Finally, the IL-10 production and suppression capacities of the B10 cells on T-cells in the patients of different disease status were investigated in order to examine their potential clinical application.
Patients and methods
Patients and healthy controls. Informed consent was obtained from 97 patients (aged ≥18 years) using the revised American College of Rheumatology criteria from 1987 (29) . The patients with RA with complicated infections were not enrolled in the present study. A total of 24 healthy individuals were recruited following informed consent as a control group and these patients were age and gender matched with the patients with RA. The Ethics Committee at Xijing Hospital (Xi'an, China) granted ethical approval of the present study. Demographic and clinical parameters were also collected at the same time as the blood and synovial samples. These included age, gender, disease duration/duration of flare, use of drugs, tender joint count (28 joints), swollen joint count (28 joints), erythrocyte sedimentation rate, level of C-reactive protein (CRP), patient global visual analogue scale (VAS; 0-10 cm), disease activity score in 28 joints (DAS28)-CRP scores, rheumatoid factor, anti-cyclic citrullinated peptide 2 antibodies, anti-mutated citrullinated vimentin antibody, and immunoglobulins, immunoglobulin (Ig)G, IgM, and IgM.
A total of 22 patients reached a DAS value of <2.6 for at least 6 months and were in clinical DAS28 remission. Out of the 75 patients with active disease, 51 individuals received no treatment or were only treated with non-steroidal anti-inflammatory drugs (NSAIDs), while 24 patients experienced a disease relapse. A flare was defined as any increase in the disease activity (DAS28≥2.6) and required a change in therapy (30) .
B-cell surface and cytoplasmic expression analysis.
Mononuclear cells in PB (PBMCs) and SF (SFMCs) were isolated by density gradient centrifugation using Ficoll-Hypaque (1.077 g/ml; Sigma-Aldrich, St. Louis, MO, USA) and were centrifuged at 400 x g for 30 min at room temperature. PBMCs and SFMC were re-suspended for 48 h prior to stimulation (2x10 6 cells/ml) in a RPMI-1640 medium containing 10% fetal calf serum (Invitrogen Life Technologies, Carlsbad, CA, USA), 4 mM L-glutamine (Invitrogen Life Technologies), 10 µg/ml lipopolysaccharide (LPS; Sigma-Aldrich) and 1 µg/ml CD40L (R&D Systems, Minneapolis, MN, USA). Phorbol myristate acetate (PMA; 50 ng/Ml, Sigma-Aldrich), ionomycin (1 µg/ml; Sigma-Aldrich) and GolgiPlug (Brefeldin A; BD Biosciences, San Jose, CA, USA) were added 5 h prior the end of the culture. Following harvesting, B-cell phenotypic analysis was performed using fluorescent-conjugated mouse anti-human monoclonal antibodies against human CD19-APC (cat. no. 555415), CD24-PerCP-Cy5.5 (cat. no. 561647), and CD38-FITC (cat. no. 555459) for 30 min on ice in the dark. The antibodies were purchased from BD Biosciences. The cytoplasmic IL-10 expression was analyzed according to the manufacturer's instructions, using a Cytofix/Cytoperm kit (BD Biosciences) and staining with anti-human IL-10 or an isotype-matched control. Subsequently, the cells were analyzed using flow cytometry (FACSort; BD Biosciences).
Serum cytokine concentration assays. Quantitative levels of cytokines IL-1β, IL-6, IL-21, IL-8, IL-17A and interferon (IFN)-γ were measured in the serum of the patients, following the manufacturer's instructions (BD Biosciences). In brief, six bead populations with distinct fluorescence intensities coated with capture antibodies specific for IL-1β, IL-6, IL-21, IL-8, IL-17A, and IFN-γ were mixed and added to each assay tube at room temperature followed by incubation for 3 h. Cells were then washed with wash buffer and re-suspended in a wash buffer prior to detection using flow cytometry. The data were analyzed using the BD CBA analysis software (FCAP Array v3.0; BD Biosciences). The concentration of each cytokine in the plasma was determined in reference to a standard curve.
Cell sorting and functional assays. A total of five patients with active disease and three healthy controls provided formal consent for the attainment of an additional 200-300 ml PB, which was necessary for cell sorting and functional assays. Table I details the characteristics of the five patients and the three healthy controls. PBMCs were isolated as described above. The CD19 + CD24 hi CD38 hi cells were separated using a fluorescence-activated cell sorting Moflo sorter (Beckman Coulter, Inc, Brea, CA, USA) following surface staining using fluorescently-conjugated antibodies against CD24, CD19 and CD38. CD3 + T cells were later enriched using MicroBeads (Miltenyi Biotech, Bergisch Gladbach, Germany) according to the manufacturer's instructions. hi cells served as a control. The proliferation of CD3 + T cells was observed using carboxyfluorescein succinimidyl ester (CFSE; Molecular Probes, Eugene, OR, USA) staining, which was quantified by flow cytometric analysis. ELISA was used to detect the cytokine tumor necrosis factor (TNF)-α in the supernatant using an IFN-γ high sensitivity ELISA (cat. no. BMS228HS; eBioscience, San Diego, CA, USA).
Statistical analysis. Statistical analyses were performed using SPSS 10.0 statistical software (SPSS, Inc., Chicago, IL, USA). For all the comparisons described in the present study Mann-Whitney U-test or t-test were used. P<0.05 was considered to indicate a statistically significant difference. Correlations were investigated using Spearman's rank correlation coefficient. (Fig. 1B) . However, regardless of the disease status, the frequency of IL-10 + B cells was higher in the SF as compared with that in the paired PB samples (Fig. 1C ). An additional analysis was conducted on patients that received no treatment or were treated only with NSAIDs, and patients with RA with a disease relapse and an active disease status (Fig. 1D) (Fig. 1E ). In addition, the individuals with ≤1% IL-10 + B cells exhibited a longer symptom duration, a greater number of tender and swollen joints, and a higher patient global visual analogue scale and DAS28-CRP, respectively (Table II) .
Results

Heterogeneity in the frequency
IL-10 + B cells were isolated by flow cytometry for further functional assays, in which the phenotype of the IL-10 + B cells was identified. As Fig. 1F demonstrates, the CD19 + CD24 hi CD38 hi cells predominantly produced IL-10 following the treatment described above. Thus, regulatory B10 cells predominantly represent a small sub-set of cells within the CD19 + CD24 hi CD38 hi B-cell sub-population, which was consistent with the findings of previous studies (26, 27) . were significantly increased in the serum of patients with RA with active disease as compared with those in the healthy controls, neither of these cytokines demonstrated any correlation with the B10 cells (Table III) .
Function of B10 cell heterogeneity in patients with RA. CD19 + CD24 hi CD38 hi cells were isolated from five patients with RA with active disease (the frequency of IL-10 + B cells was ≤1% in two patients and 1% in three patients) and three healthy controls (Table I) . Following 48-h treatment with LPS plus CD40 L, the CD19 + CD24 hi CD38 hi cells isolated from patients in whom the IL-10 + B-cell frequency was ≤1% secreted significantly lower levels of IL-10 compared with those from the healthy controls (6.24±2.31 vs. 13.64±3.77; P<0.001) and (Fig. 2A) .
CFSE labeling of the respective cells was used to assess the effect of B10 cells on the proliferation of CD3 + T cells. This dye was retained in the cytoplasm and was diluted with each cell division. As shown in Fig. 2B, (Fig. 2C) .
Discussion
In the present study, the heterogeneity in the frequency of IL-10-competent CD19 + B cells in patients with RA with different disease status was demonstrated, which was in parallel with their inhibitory effect on CD3 + T cells. The median frequency of B10 cells was significantly higher in RA patients with an active disease as compared with that in the healthy controls and patients with RA in remission.
Recent studies on B10 cells in animal models demonstrated that IL-10-competent B-cells exerted profoundly negative regulatory functions on innate and adaptive immunity, and revealed their therapeutic potential in the treatment of autoimmune diseases (15) . However, studies of IL-10-competent B-cells in humans yielded diverse results, which were difficult to unify into a coherent model. In 2009, Blair et al (26) identified a specific sub-set of human Breg cells with a phenotype of CD19 + CD24 hi CD38 hi , which were previously associated with immature transitional B-cells, but were able to produce IL-10 in response to stimulation in vitro. In this study, CD19 + CD24 hi CD38 hi cells from patients with SLE secreted low levels of IL-10 and exerted defective suppressive effects on CD4 + T cells as opposed to those from healthy controls. Sequentially, a deficit of this B10-cell suppressive ability was also found in patients with immune thrombocytopenia (28) . A recent study revealed that patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis had diminished levels of IL-10-producing B-cells (32) . All of these results indicated that B10-cell dysfunction may be implicated in a number of diseases in humans.
RA is an auto-inflammatory disease that is characterized by complex pathogenic inflammation that differs from SLE and ANCA-associated vasculitis. Although several studies (12,17,21) Table II . Demographic and clinical characteristics of patients with RA with active disease. on CIA demonstrated the negative regulatory effects and therapeutic potential of B10 cells in RA treatment, the characteristics of B10 cells in patients with RA have not been well-investigated. In 2011, Iwata et al (25) reported that IL-10-producing B-cells increased in the PB of patients with RA. However, the authors did not correlate the characteristics of B10 cells in patients with RA with different disease stages as only 19 patients were recruited in the study. It was therefore critical to further assess the characteristics of B10 cells in patients with RA prior to their use in the clinical practice. Therefore, the present study recruited a total of 97 patients with RA with a range of disease statuses. The results revealed that the frequency of B10 cells significantly increased in the patients with RA with an active disease status compared with that of patients with RA in remission or in healthy controls. This suggested that the inflammatory factors increased the frequency of B10. This was confirmed by the observed higher frequency of B10 cells in the SF as compared with that in the PB of the patients with RA. The frequency of B10 cells at low, moderate and high disease severity status revealed no significant differences, which suggested that the disease status did not affect the frequency of B10 cells. B10 cells from patients with RA with an active disease status were also investigated and it was found that the frequency of B10 cells exhibited no difference between an untreated sub-group and a sub-group undergoing a disease relapse. This indicated that the frequency of B10 cells was not affected by previous therapy. It is important to note that a small group of patients with active RA with a high disease status that received no treatment were found to exhibit a significantly decreased frequency of IL-10 + B cells (≤1%). When compared with patients with >1% IL-10 + B cells in the untreated group and the patients with a disease relapse, the individuals in the ≤1% IL-10 + B-cell sub-group exhibited a significantly longer symptom duration, a greater number of tender and swollen joints and a higher global VAS and DAS28-CRP score for the demographic and clinical characteristics. In order to further investigate the factors that affected the frequency of B10 cells in the patients with RA, the correlation of the B10-cell frequency in the blood with the clinical characteristics was assessed. It was identified that the B-cell frequency exhibited a negative correlation with symptom duration and the number of swollen joints, which suggested that disease duration and inflammatory factors may be critical in decreasing the B10-cell frequency. As the pro-inflammatory cytokines, including IL-1β, IL-6, IL-21, IL-8, IL-17A, and IFN-γ, are considered to have an important pathogenic role in RA and were produced at increased levels in the patients with RA with an active disease status compared with those in the other groups, a correlation analysis of these cytokines with the B10-cell frequency was also performed. However, no significant correlation was identified between these inflammatory factors and B10-cell frequency. This indicated that multiple factors in the regulation of B10-cell production and other unknown inflammatory cytokines may have affected the B10-cell frequency in patients with RA.
RA with no treatment/NSAID ------------------------------------------------------------------------------------------------
Subsequently, the regulatory ability of B10 cells on the proliferation of CD3 + T cells was assessed. It was identified that CD19 + CD24 hi CD38 hi cells predominantly produced IL-10, which was consistent with previous studies (25) (26) (27) . Therefore, they have been termed ̔B10 cells̓ in recent years (26) . Similarly, based on the observations regarding B10-cell frequency detection, the B10 cells from patients with RA with different disease status revealed heterogenic functions. The B10 cells isolated from the RA sub-group containing ≤1% IL-10 + B cells secreted significantly decreased levels of IL-10 and exerted a significantly diminished suppressive effect on CD3 + T-cell proliferation and TNF-α production compared with those of healthy controls and the RA sub-group containing >1%IL-10 + B10 cells. These functional studies on B10 cells further demonstrated the complexity of the mechanisms underlying B10-cell generation and function in patients with RA.
In conclusion, the present study demonstrated that the frequency and function of B10 cells displayed heterogeneity in patients with RA with a different disease status as well as healthy controls. Adoptive transfer of B10 cells is considered to be a potential therapeutic strategy for RA based on the results of previous studies on animals; however, further study is required prior to the use of B10 cells in clinical practice.
